IL233863A - Pyridine derivatives, preparations containing them and their uses - Google Patents

Pyridine derivatives, preparations containing them and their uses

Info

Publication number
IL233863A
IL233863A IL233863A IL23386314A IL233863A IL 233863 A IL233863 A IL 233863A IL 233863 A IL233863 A IL 233863A IL 23386314 A IL23386314 A IL 23386314A IL 233863 A IL233863 A IL 233863A
Authority
IL
Israel
Prior art keywords
compositions
same
pyridone derivatives
pyridone
derivatives
Prior art date
Application number
IL233863A
Other languages
English (en)
Hebrew (he)
Other versions
IL233863A0 (en
Original Assignee
Daiichi Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Co Ltd filed Critical Daiichi Sankyo Co Ltd
Publication of IL233863A0 publication Critical patent/IL233863A0/en
Publication of IL233863A publication Critical patent/IL233863A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D451/00Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81Amides; Imides
    • C07D213/82Amides; Imides in position 3
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IL233863A 2012-01-31 2014-07-30 Pyridine derivatives, preparations containing them and their uses IL233863A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2012017971 2012-01-31
US201261746039P 2012-12-26 2012-12-26
PCT/JP2013/052111 WO2013115280A1 (ja) 2012-01-31 2013-01-30 ピリドン誘導体

Publications (2)

Publication Number Publication Date
IL233863A0 IL233863A0 (en) 2014-09-30
IL233863A true IL233863A (en) 2017-08-31

Family

ID=48905312

Family Applications (1)

Application Number Title Priority Date Filing Date
IL233863A IL233863A (en) 2012-01-31 2014-07-30 Pyridine derivatives, preparations containing them and their uses

Country Status (30)

Country Link
US (1) US8933103B2 (enExample)
EP (1) EP2810937B1 (enExample)
JP (1) JP6006241B2 (enExample)
KR (1) KR102078530B1 (enExample)
CN (1) CN104185627B (enExample)
AU (1) AU2013216006B2 (enExample)
BR (1) BR112014018702B1 (enExample)
CA (1) CA2863515C (enExample)
CO (1) CO7071126A2 (enExample)
CY (1) CY1118656T1 (enExample)
DK (1) DK2810937T3 (enExample)
ES (1) ES2617484T3 (enExample)
HR (1) HRP20170303T1 (enExample)
HU (1) HUE031624T2 (enExample)
IL (1) IL233863A (enExample)
LT (1) LT2810937T (enExample)
MX (1) MX351812B (enExample)
MY (1) MY165215A (enExample)
NZ (1) NZ627586A (enExample)
PH (1) PH12014501719B1 (enExample)
PL (1) PL2810937T3 (enExample)
PT (1) PT2810937T (enExample)
RS (1) RS55728B1 (enExample)
RU (1) RU2632885C2 (enExample)
SG (1) SG11201404505PA (enExample)
SI (1) SI2810937T1 (enExample)
SM (2) SMT201700065T1 (enExample)
TW (1) TWI537259B (enExample)
WO (1) WO2013115280A1 (enExample)
ZA (1) ZA201405486B (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013162061A1 (ja) * 2012-04-26 2013-10-31 第一三共株式会社 二環性ピリミジン化合物
ES2685661T3 (es) * 2013-11-08 2018-10-10 Ono Pharmaceutical Co., Ltd. Derivado de pirrolopirimidina
CA2929188C (en) 2013-11-20 2022-08-09 Signalchem Lifesciences Corp. Quinazoline derivatives as tam family kinase inhibitors
US10233176B2 (en) 2013-11-27 2019-03-19 Signalchem Lifesciences Corporation Aminopyridine derivatives as TAM family kinase inhibitors
CA2946538A1 (en) 2014-04-04 2015-10-08 Del Mar Pharmaceuticals Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer
TWI723572B (zh) 2014-07-07 2021-04-01 日商第一三共股份有限公司 具有四氫吡喃基甲基之吡啶酮衍生物及其用途
US9840503B2 (en) 2015-05-11 2017-12-12 Incyte Corporation Heterocyclic compounds and uses thereof
WO2017027717A1 (en) 2015-08-12 2017-02-16 Incyte Corporation Bicyclic fused pyrimidine compounds as tam inhibitors
WO2017035366A1 (en) 2015-08-26 2017-03-02 Incyte Corporation Pyrrolopyrimidine derivatives as tam inhibitors
US20190099413A1 (en) 2016-02-26 2019-04-04 Ono Pharmaceutical Co., Ltd. Drug for cancer therapy characterized in that axl inhibitor and immune checkpoint inhibitor are administered in combination
EP3436461B1 (en) 2016-03-28 2023-11-01 Incyte Corporation Pyrrolotriazine compounds as tam inhibitors
CN108250200A (zh) * 2016-12-28 2018-07-06 中国科学院上海药物研究所 一种具有Axl抑制活性的化合物及其制备和应用
EP3673907A4 (en) 2017-08-23 2020-08-19 ONO Pharmaceutical Co., Ltd. CANCER TREATMENT PHARMACEUTICAL INCLUDING AX1 INHIBITOR AS AN EFFECTIVE INGREDIENT
MY208007A (en) 2017-09-27 2025-04-04 Incyte Corp Salts of pyrrolotriazine derivatives useful as tam inhibitors
JP7223998B2 (ja) 2017-10-13 2023-02-17 小野薬品工業株式会社 Axl阻害剤を有効成分として含む固形がん治療剤
CN112243374A (zh) * 2018-01-29 2021-01-19 卡普勒斯疗法有限责任公司 包括6元中心环的srebp抑制剂
CN112074505B (zh) 2018-03-08 2024-04-05 因赛特公司 作为PI3K-γ抑制剂的氨基吡嗪二醇化合物
AR117600A1 (es) 2018-06-29 2021-08-18 Incyte Corp Formulaciones de un inhibidor de axl / mer
US11046658B2 (en) 2018-07-02 2021-06-29 Incyte Corporation Aminopyrazine derivatives as PI3K-γ inhibitors
TWI840378B (zh) * 2018-07-04 2024-05-01 日商第一三共股份有限公司 二芳基吡啶衍生物之製造方法
WO2020038460A1 (zh) * 2018-08-24 2020-02-27 南京药捷安康生物科技有限公司 一种新型的喹啉衍生物抑制剂
KR20210142154A (ko) 2019-03-21 2021-11-24 옹쎄오 암 치료를 위한 키나제 억제제와 조합된 dbait 분자
US11718612B2 (en) 2019-09-06 2023-08-08 Board Of Regents, The University Of Texas System Inhibitors of receptor interacting protein kinase I for the treatment of disease
CN112625026B (zh) * 2019-09-24 2022-09-09 药捷安康(南京)科技股份有限公司 Tam家族激酶抑制剂的喹啉衍生物
IL291665B2 (en) 2019-09-27 2025-07-01 Univ Texas Inhibitors of receptor interacting protein kinase i for the treatment of disease
CN114761006A (zh) 2019-11-08 2022-07-15 Inserm(法国国家健康医学研究院) 对激酶抑制剂产生耐药性的癌症的治疗方法
WO2021108198A1 (en) * 2019-11-26 2021-06-03 Board Of Regents, The University Of Texas System Inhibitors of receptor interacting protein kinase i for the treatment of disease
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
EP4114401A1 (en) 2020-03-06 2023-01-11 Incyte Corporation Combination therapy comprising axl/mer and pd-1/pd-l1 inhibitors
JPWO2022220227A1 (enExample) * 2021-04-14 2022-10-20

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL205322B1 (pl) * 1999-05-07 2010-04-30 Encysive Pharmaceuticals Inc Pochodne kwasu propionowego, środek farmaceutyczny i zastosowanie pochodnych kwasu propionowego
EP1136485A1 (en) * 2000-03-23 2001-09-26 Sanofi-Synthelabo Aminophenyl pyrimidone derivatives
IL163547A0 (en) 2002-02-12 2005-12-18 Quark Biotech Inc Use of the axl receptor for diagnosis and treatment of renal disease
WO2007030680A2 (en) 2005-09-07 2007-03-15 Rigel Pharmaceuticals, Inc. Triazole derivatives useful as axl inhibitors
WO2007057399A2 (en) 2005-11-15 2007-05-24 Boehringer Ingelheim International Gmbh Treatment of cancer with indole derivatives
BRPI0619424B1 (pt) 2005-12-05 2022-02-08 Pfizer Products Inc Uso de inibidores c-met/hgfrs para a fabricação de medicamentos
JP5400388B2 (ja) 2005-12-15 2014-01-29 ライジェル ファーマシューティカルズ, インコーポレイテッド キナーゼインヒビターおよびその利用
EP1900727A1 (en) 2006-08-30 2008-03-19 Cellzome Ag Aminopyridine derivatives as kinase inhibitors
WO2008045978A1 (en) 2006-10-10 2008-04-17 Rigel Pharmaceuticals, Inc. Pinane-substituted pyrimidinediamine derivatives useful as axl inhibitors
GB0625659D0 (en) 2006-12-21 2007-01-31 Cancer Rec Tech Ltd Therapeutic compounds and their use
US8012965B2 (en) 2006-12-29 2011-09-06 Rigel Pharmaceuticals, Inc. Bridged bicyclic aryl and bridged bicyclic heteroaryl substituted triazoles useful as axl inhibitors
ME01832B (me) 2006-12-29 2014-12-20 Rigel Pharmaceuticals Inc Policiklični heteroaril supstituisani triazoli koji su korisni kao axl inhibitori
EP2114954B1 (en) 2006-12-29 2013-02-13 Rigel Pharmaceuticals, Inc. Bicyclic aryl and bicyclic heteroaryl substituted triazoles useful as axl inhibitors
US9650391B2 (en) 2006-12-29 2017-05-16 Rigel Pharmaceuticals Inc. N3-heteroaryl substituted triazoles and N5-heteroaryl substituted triazoles useful as Axl inhibitors
ES2656496T3 (es) 2006-12-29 2018-02-27 Rigel Pharmaceuticals, Inc. Triazoles sustituidos útiles como inhibidores de AXL
CA2682733A1 (en) 2007-04-13 2008-10-23 Supergen, Inc. Axl kinase inhibitors
GB0713259D0 (en) 2007-07-09 2007-08-15 Astrazeneca Ab Pyrazine derivatives 954
JP2010533159A (ja) * 2007-07-09 2010-10-21 アストラゼネカ アクチボラグ 化合物947
WO2009024825A1 (en) 2007-08-21 2009-02-26 Astrazeneca Ab 2-pyrazinylbenzimidazole derivatives as receptor tyrosine kinase inhibitors
GB0719803D0 (en) 2007-10-10 2007-11-21 Cancer Rec Tech Ltd Therapeutic compounds and their use
RU2010120536A (ru) * 2007-10-25 2011-11-27 Астразенека Аб (Se) Производные пиридина и пиразина, полезные для лечения клеточных проферативных расстройств
MX2010004491A (es) * 2007-10-25 2010-06-21 Astrazeneca Ab Derivados de piridina y pirazina utiles en el tratamiento de trastornos proliferativos celulares.
EP2205592B1 (en) * 2007-10-26 2013-05-08 Rigel Pharmaceuticals, Inc. Polycyclic aryl substituted triazoles and polycyclic heteroaryl substituted triazoles useful as axl inhibitors
JP2011502991A (ja) 2007-11-02 2011-01-27 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 骨癌並びに骨癌に伴う骨喪失及び骨痛の処置又は予防のためのcfms阻害物質の使用
KR101596527B1 (ko) 2008-01-23 2016-02-22 브리스톨-마이어스 스큅 컴퍼니 4-피리디논 화합물 및 암에 대한 그의 용도
JP5693239B2 (ja) 2008-01-23 2015-04-01 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company 4−ピリジノン化合物および癌についてのその使用
KR101325237B1 (ko) 2008-04-16 2013-11-04 막스-플랑크-게젤샤프트 츄어 푀르더룽 데어 비쎈샤프텐 에.파우. Axl 키나아제 억제제인 퀴놀린 유도체
UY31800A (es) 2008-05-05 2009-11-10 Smithkline Beckman Corp Metodo de tratamiento de cancer usando un inhibidor de cmet y axl y un inhibidor de erbb
WO2009138799A1 (en) 2008-05-14 2009-11-19 Astex Therapeutics Limited Therapeutic uses of 1-cycl0pr0pyl-3 - [3- ( 5 -morpholin- 4 -ylmethyl- 1h-benz0imidaz0l- 2 -yl) -lh-pyrazol-4-yl] -urea
JP5592884B2 (ja) 2008-07-09 2014-09-17 ライジェル ファーマシューティカルズ, インコーポレイテッド Axl阻害剤として有用な多環式ヘテロアリール置換トリアゾール
SI2328888T1 (sl) 2008-07-09 2013-03-29 Rigel Pharmaceuticals, Inc. Premoščeni biciklični heteroaril substituirani triazoli, uporabni kot inhibitorji Axl
SG172857A1 (en) 2009-02-09 2011-08-29 Supergen Inc Pyrrolopyrimidinyl axl kinase inhibitors
BRPI1015259A2 (pt) * 2009-04-27 2016-05-03 Elan Pharm Inc antagonistas de piridinona de integrinas alfa-4
EP2311809A1 (en) 2009-10-16 2011-04-20 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Quinolinyloxyphenylsulfonamides
JP5970003B2 (ja) 2011-03-04 2016-08-17 ローカス ファーマシューティカルズ インコーポレイテッド アミノピラジン化合物

Also Published As

Publication number Publication date
US8933103B2 (en) 2015-01-13
PL2810937T3 (pl) 2017-07-31
MX2014009246A (es) 2014-10-14
RU2632885C2 (ru) 2017-10-11
BR112014018702A2 (enExample) 2017-06-20
HK1203504A1 (en) 2015-10-30
ZA201405486B (en) 2015-11-25
AU2013216006B2 (en) 2017-06-08
SI2810937T1 (sl) 2017-01-31
EP2810937A4 (en) 2015-07-22
JP6006241B2 (ja) 2016-10-12
EP2810937B1 (en) 2016-11-30
CA2863515C (en) 2018-02-27
RU2014135401A (ru) 2016-03-20
HRP20170303T1 (hr) 2017-04-21
CY1118656T1 (el) 2017-07-12
WO2013115280A1 (ja) 2013-08-08
CO7071126A2 (es) 2014-09-30
BR112014018702A8 (pt) 2017-07-11
JPWO2013115280A1 (ja) 2015-05-11
HUE031624T2 (en) 2017-07-28
NZ627586A (en) 2016-08-26
PT2810937T (pt) 2017-03-03
CN104185627B (zh) 2018-01-12
US20130281428A1 (en) 2013-10-24
AU2013216006A1 (en) 2014-08-28
PH12014501719A1 (en) 2014-11-10
TW201335148A (zh) 2013-09-01
KR102078530B1 (ko) 2020-02-18
IL233863A0 (en) 2014-09-30
SMT201700065B (it) 2017-03-08
EP2810937A1 (en) 2014-12-10
KR20140117439A (ko) 2014-10-07
CN104185627A (zh) 2014-12-03
MY165215A (en) 2018-03-09
ES2617484T3 (es) 2017-06-19
PH12014501719B1 (en) 2019-07-17
LT2810937T (lt) 2017-02-10
TWI537259B (zh) 2016-06-11
SMT201700065T1 (it) 2017-03-08
RS55728B1 (sr) 2017-07-31
CA2863515A1 (en) 2013-08-08
SG11201404505PA (en) 2014-10-30
BR112014018702B1 (pt) 2021-12-14
MX351812B (es) 2017-10-27
DK2810937T3 (en) 2017-03-13

Similar Documents

Publication Publication Date Title
IL233863A0 (en) Pyridine derivatives, preparations containing them and their uses
IL236348A0 (en) Anti-Jagad antibodies, preparations containing them and their uses
IL228322A0 (en) History of dispiropyrrolidine, preparations containing them and their uses
IL234014A (en) Cycloalkane derivatives, preparations containing them and their uses
IL227963A0 (en) History History of cytotoxic benzodiazepines, preparations containing them and their uses
IL269964A (en) Pyridone amide compounds, compositions containing them and uses thereof
IL237625A0 (en) Antibodies against m-cam, preparations containing them and their uses
IL235767A (en) Preserved pyrolidines, pharmaceuticals containing them and their uses
IL233154A (en) Compounds, pharmaceuticals containing them and their uses
IL238958A0 (en) Glutamase inhibitors, preparations containing them and their uses
IL223361A (en) Purinone history, preparations containing them and their uses
IL238959A (en) Glutamase suppressors, preparations containing them and their uses
IL235004A0 (en) Antibodies against fgfr2, preparations containing them and their uses
IL237068A (en) 1,3-dioxanomorphides and 1,3-dioxanocodides
IL236057B (en) History of 4,2,1-triazine-6-carboxamide and pharmaceutical preparations containing them
IL241355B (en) Pyrazole-amide compounds, preparations containing them and their uses
IL235585A0 (en) Substances that bind to ha, preparations containing them and their uses
IL238825B (en) The history of heterocyclics, their preparation and pharmaceutical preparations containing them
IL233824A (en) Compounds 1h - Indazole - 3 - Carboxamide, preparations containing them and their use
IL236712A0 (en) Di-teri-heteroaryl derivatives, preparations containing them and their uses
IL223405B (en) Phosphoplatins, preparations containing them and their uses
IL233602A0 (en) History of benzamide, their preparation and pharmaceutical preparations containing them
IL246006A0 (en) 5-hydroxy-4 (trifluoromethyl)pyrazolopyridine derivatives, preparations containing them and their uses
IL251177A0 (en) Parasitic preparations containing benzaimidazole history, methods and uses
IL237542B (en) Amphiphilic compounds, their preparations and uses

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed